UnitedHealth Group (UNH)
International Stocks
Sell
The speaker interprets the effects of uncertainty in Medicare reimbursement rates and rising costs on company profitability.
Jared (Analyst)
Yahoo Finance
Loading...
Loading...
Coverage, strength, recency, conviction and momentum.
Covered by 5 analysts
Mixed views among analysts
Last evaluation 85+ days ago - stale data
Both buy and sell recommendations exist
Decreasing interest recently
Newest calls at the top.
The speaker interprets the effects of uncertainty in Medicare reimbursement rates and rising costs on company profitability.
Analyzes the disappointing revenue forecast and the impact of lower Medicare reimbursement rates on the stock's performance.
The speaker announces that the company will voluntarily eliminate and rebate its profits from ACA individual plans this year. This strategic decision aims to address affordability concerns amidst political scrutiny, though it impacts the profitability of that specific segment.
The speaker examines the findings of a Senate investigation alleging the company used aggressive tactics to boost diagnoses for Medicare Advantage payments.
The speaker analyzes the potential outcome of healthcare legislation, suggesting that bipartisan efforts might inadvertently strengthen the largest market players.
The analyst explains the long-term turnaround expectation and price target based on the company's fundamentals.
The analyst examines the stabilization in UnitedHealthcare following a pricing super cycle, highlighting a recovery in margins from current lows and reduced exposure to government marketplace risks.
The speaker evaluates the company's signs of recovery and earnings growth expectations for 2026 despite medical cost management and Medicare Advantage challenges.
The speaker interprets the effects of uncertainty in Medicare reimbursement rates and rising costs on company profitability.
Analyzes the disappointing revenue forecast and the impact of lower Medicare reimbursement rates on the stock's performance.
The speaker announces that the company will voluntarily eliminate and rebate its profits from ACA individual plans this year. This strategic decision aims to address affordability concerns amidst political scrutiny, though it impacts the profitability of that specific segment.
The speaker examines the findings of a Senate investigation alleging the company used aggressive tactics to boost diagnoses for Medicare Advantage payments.
The speaker analyzes the potential outcome of healthcare legislation, suggesting that bipartisan efforts might inadvertently strengthen the largest market players.
The analyst explains the long-term turnaround expectation and price target based on the company's fundamentals.